PRESS RELEASE




Availability of Transgene’s
2024 Universal Registration Document (URD)


Strasbourg, April 10, 2025, 08:15 pm CET


Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based
immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal
Registration Document was filed with the French Financial Markets Authority (Autorité des marchés
financiers – AMF) on April 10, 2025, under number D.25-0243.

This document, available on the AMF’s website (www.amf-france.org), can be viewed and downloaded (in
PDF format in French and English, and in ESEF format in French only) on Transgene’s website
(www.transgene.fr)

It includes the following documents:

- the Annual Financial Report;
- the Board of Directors’ Corporate Governance Report;
- the Statutory Auditors’ Reports;
- information on the Company’s share capital, including the share buyback program;
- information on the Statutory Auditors’ fees.

The Universal Registration Document also includes information on the Company’s Environmental, Social
and Governance (ESG) factors.




1/1